A practical reference on Ac-LKKTETQ: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-14. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
=== Atrial Natriuretic Peptide (ANP) === The human gene that makes ANP is called NPPA, and it's on chromosome 1 at location 1p36.21. The gene is about two kilobases long and has three parts called exons and two called introns. The mRNA from this gene makes a protein called preproANP with 151 parts called amino acids. The first 25 parts are removed to create a 126-part protein called proANP which is stored in the atrial granules. When the body needs ANP, Corin (an enzyme) breaks apart proANP to make the active form of ANP, which is 28 amino acids long.
Trepanging is the act of collecting or harvesting sea cucumbers (Indonesian: trepang, Malay: těripang) that are used as food. The collector, or fisher, of trepang is a trepanger. Trepanging is comparable to clamming, crabbing, lobstering, musseling, shrimping and other forms of "fishing" whose goal is the acquisition of edible invertebrates rather than fish.
==== Intangible Cultural Heritage of Humanity ==== Kimchi-related items have been inscribed on UNESCO's Representative List of the Intangible Cultural Heritage of Humanity by both South and North Korea. This makes kimchi the second intangible heritage that was submitted by two countries, the other one being the folk song "Arirang" which was also submitted by both North and South Korea. "The culture of kimjang" was the subject of the Intangible Cultural Heritage: kimchi is not registered by itself.
Sources: en.wikipedia.org
She said that "This has nothing to do with tension or relations between Delcy Rodriguez and myself," and discussed that the "criminal structure" that has dominated Venezuela for years would eventually dismantle itself. A week later, Trump said he was considering involving Machado in his plans on Venezuela in some way, without specifying which role she would play. On 26 January, after a hearing on Venezuela on the US Senate, Marco Rubio met with Machado. She later said to reporters that a change in Venezuela was coming. Venezuelan TV network Venevisión broadcast Machado message after meeting with Rubio. According to the Venezuelan national press workers union, the state regulator later cut Venevision's access to some satellite TV providers. In an interview of NBC, Delcy Rodríguez said about Machado that "She will have to answer to Venezuela why she called upon a military intervention, why she called upon sanctions to Venezuela, and why she celebrated the actions that took place at the beginning of January." At Machado's request, she met for a second time with Donald Trump in the White House on 6 March to review plans for her trip to come back to Venezuela. In September 2026, Machado's reported about seven failed attempts to enter the country by air and sea, at least three while Delcy Rodríguez was away during a UN General Assembly.
By 1960, it was the fund's most successful investment, and its returns helped demonstrate the viability of venture investing in start-ups. After federal science funding contracted in the late 1960s, HVEC ceased accelerator production and reorganized as a conglomerate. The company was taken private in 1988 and filed for bankruptcy in 2005.
== Sustainability == Sustainability has become a major policy objective in South Africa's logistics sector. Because road freight dominates the country's land freight system, most sustainability initiatives focus on reducing emissions from trucking, while increasing the use of rail. 2025 research on the Gauteng province's freight industry showed that many road freight companies are adopting green logistics practices, primarily through increased operational efficiency. Measures include route optimization, higher vehicle utilization and backhauling, lower-emission trucks, the use of alternative fuels, and the electrification of suitable fleets. South Africa's warehouses and logistics facilities are increasingly incorporating rooftop solar photovoltaic systems, battery storage systems, electric material-handling equipment, and energy-efficient refrigeration. Energy efficient warehousing is one of the fastest-growing sustainability measures in the South African logistics sector. Sustainable freight corridors continue to be developed in South Africa. A network of off-grid solar-powered charging infrastructure for heavy-duty electric trucks is being rolled out along major highways, by Cape Town-based company Charge. The EV charging network operator, founded in 2021, is installing 120 charging stations, designed specifically for electric trucks. The chargers are planned to be located along the N3 freight corridor between Johannesburg and Durban, with future expansion planned along the N1 corridor.
Methanol – Caused by the demethylation of pectins in the must by enzymes of the yeast. More commonly found in red wines than white but only in very small amounts between 20 and 200 mg/L. Fusel oils – Formed by the decomposition of amino acids by the yeast. This includes 2,3-butanediol which is formed by yeast that are consuming diacetyl, the compound that gives Chardonnay and other wines a "buttery" aroma, reducing it first to acetoin and then to the more neutral-smelling 2,3-butanediol. Many beer and winemakers who have a wine with too much "butteriness" will often "pitch" fresh yeast cultures into the no longer fermenting tank so that the yeast will consume the diacetyl and reduce the aroma. Succinic acid – Like glycerol, this is often formed early in fermentation. Usually found in concentrations of 500–1200 mg/L, it is a minor acid in the overall acidity of wine. Acetic acid – Considered a main component of volatile acidity that can make a wine taste unbalanced and overly acidic. While acetic acid is the main volatile acid produced by yeast, trace amounts of butyric, formic and propionic acids can also be formed depending on the yeast strain. Most countries have wine laws setting the legal limit of volatile acidity, usually expressed as acetic acid, to 1200–2000 mg/L. Acetic acid can also lead to the development of the wine fault ethyl acetate which is characterized by a "nail polish remover" smell. However, small amounts of acetic acid are actually beneficial for the yeast as they use them to synthesis lipids in the cell membrane.
Sources: en.wikipedia.org
== Media == Ariely has appeared in several documentary films and television productions. In 2011, he worked on the documentary The Flaw, which investigates the causes of the 2008 financial crisis. In it, Ariely explained and presented scientific data on the forces that shape human behavior, motivation, and decision-making. In 2015, Ariely appeared in another documentary, (Dis)Honesty: The Truth About Lies. It explores three key themes: why people lie, how often they do it, and the consequences of dishonest behavior. Ariely contributed to Boom Bust Boom, a 2015 documentary about economic crashes. In 2019, he appeared in The Inventor: Out for Blood in Silicon Valley, a documentary that tracks the rise and fall of Theranos. In 2022, he contributed to Why Like This? Lama Kacha, a Hebrew television series broadcast on Kan 11. In it, Ariely distilled complex scientific concepts and provided accessible explanations for the forces that shape human behavior, motivation, and decision-making. Ariely has also presented talks at several TED, with titles such as "Our Buggy Moral Code" and "Unraveling the Mysteries of Human Behavior".
=== Two common regimens: pens, injection ports, and pumps === One method of intensive insulinotherapy is based on multiple daily injections (sometimes referred to in medical literature as MDI). Meal insulin is supplied by injection of rapid-acting insulin before each meal in an amount proportional to the meal. Basal insulin is provided as a once or twice daily injection of dose of a long-acting insulin. In an MDI regimen, long-acting insulins are preferred for basal use. An older insulin used for this purpose is ultralente, and beef ultralente in particular was considered for decades to be the gold standard of basal insulin. Long-acting insulin analogs such as insulin glargine (brand name Lantus, made by Sanofi-Aventis) and insulin detemir (brand name Levemir, made by Novo Nordisk) are also used, with insulin glargine used more than insulin detemir. Rapid-acting insulin analogs such as lispro (brand name Humalog, made by Eli Lilly and Company) and aspart (brand name Novolog/Novorapid, made by Novo Nordisk and Apidra made by Sanofi Aventis) are preferred by many clinicians over older regular insulin for meal coverage and high correction. Many people on MDI regimens carry insulin pens to inject their rapid-acting insulins instead of traditional syringes. Some people on an MDI regimen also use injection ports such as the I-port to minimize the number of daily skin punctures. The other method of intensive/flexible insulin therapy is an insulin pump. It is a small mechanical device about the size of a deck of cards.
=== Principal positions === Starting as a biochemist at the United States Public Health Service at the National Institutes of Health, Bethesda, Maryland from 1941 to 1959, Horecker moved to the New York University Grossman School of Medicine, until 1963, then at the Albert Einstein College of Medicine and the Roche Institute of Molecular Biology in Nutley, New Jersey and finally at Cornell University.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.